U.S. Stock Market Midday Update
Eli Lilly fell 4.86%, with increased trading volume. Based on recent important news:
<ol>
<li>
On July 29, Eli Lilly announced that its drug Jaypirca achieved its primary endpoint in the Phase III clinical trial for CLL/SLL, challenging Johnson &amp; Johnson and AbbVie’s Imbruvica. Despite positive data, the market reacted poorly, leading to a 4.86% drop in stock price.
</li>
<li>
On July 29, investors held a bearish outlook on Eli Lilly, with options trading showing significant selling pressure, further exacerbating the decline in stock price.
</li>
<li>
On July 28, the Bank of Montreal raised Eli Lilly's target price to $920, but failed to boost market confidence.
</li>
</ol>
Top Stocks by Industry Trading Volume
Novo Nordisk fell 21.28%, with a significant increase in trading volume. Based on recent important news:
<ol>
<li>
On July 29, Novo Nordisk lowered its sales growth forecast for 2025 to 8-14%, primarily due to intensified competition in the U.S. GLP-1 market, resulting in a 21.28% drop in stock price.
</li>
<li>
On July 29, Novo Nordisk appointed a new CEO, and the market expressed doubts about their ability to handle competition and expand the market, leading to further declines in stock price.
</li>
<li>
On July 29, the Chief Financial Officer stated that sales of Ozempic in the U.S. were impacted by competition, leading to a downward revision of performance outlook and putting pressure on the stock price.
</li>
</ol>
Merck fell 2.28%, with increased trading volume. Based on recent important news:
<ol>
<li>
On July 29, Merck announced its second-quarter financial report, with net profit down 20.3% year-on-year. The stock price initially fell by 8.8%, but the decline narrowed to 3.3%.
</li>
<li>
On July 29, Merck announced a $3 billion cost-cutting plan to address competition from Keytruda generics, leading to a sharp decline in stock price.
</li>
<li>
On July 29, the full-year sales forecast was lowered to $64.3 billion to $65.3 billion, with a negative market reaction.
</li>
</ol>
AstraZeneca rose 3.17%, with increased trading volume. Based on recent important news:
<ol>
<li>
On July 29, AstraZeneca announced its second-quarter financial report, with profits exceeding expectations due to strong sales of cancer drugs, resulting in a 3.17% increase in stock price.
</li>
<li>
On July 29, AstraZeneca announced a $50 billion investment in the U.S. to expand production and R&amp;D capabilities, boosting market confidence.
</li>
<li>
On July 29, AstraZeneca maintained its full-year performance forecast, demonstrating confidence in future development and driving up stock price.
</li>
</ol>
Top Stocks by Industry Market Capitalization
Johnson &amp; Johnson rose 0.91%, with a market capitalization of $403.9 billion. Based on recent important news:
<ol>
<li>
On July 29, Johnson &amp; Johnson submitted a supplemental biologics license application, adding new evidence for TREMFYA in psoriatic arthritis, which boosted stock price.
</li>
<li>
On July 29, Johnson &amp; Johnson launched the VirtuGuide™ AI system to streamline bunion surgery, enhancing market confidence
</li>
<li>
On July 28, analysts raised Johnson &amp; Johnson's target price to $165, reflecting optimistic market expectations
</li>
</ol>

Eli Lilly fell 4.86%; Novo Nordisk fell 21.28%, with a transaction volume of USD 5.189 billion; Merck fell 2.28%, with a transaction volume of USD 1.663 billion; AstraZeneca rose 3.17%, with a transaction volume of USD 897 million; Johnson & Johnson rose 0.91%, with a market value of USD 403.9 billion

U.S. stock market update: Eli Lilly down 4.86%